美沙拉嗪联合丹参酮Ⅱ_(A)治疗溃疡性结肠炎临床研究  

Clinical Study of Mesalazine Combined with TanshinoneⅡ_(A)in the Treatment of Ulcerative Colitis

作　　者：符晶[1] 谭琰 符白玉 FU Jing;TAN Yan;FU Baiyu(Department of Gastroenterology,The First Affiliated Hospital of Hainan Medical University,Haikon,Hainan,China 570102)

机构地区：[1]海南医学院第一附属医院消化内科,海南海口570102

出　　处：《中国药业》2021年第14期48-51,共4页China Pharmaceuticals

基　　金：海南省自然科学基金[819MS063]。

摘　　要：目的探讨美沙拉嗪联合丹参酮ⅡA治疗溃疡性结肠炎的临床疗效,以及对患者肠黏膜环氧化酶-2(COX-2)及核因子κB(NF-κB)水平的影响。方法选取医院2018年1月至2020年1月收治的溃疡性结肠炎患者80例,按治疗方法的不同分为对照1组(25例)、对照2组(25例)和观察组(30例)。对照1组患者予美沙拉嗪肠溶片口服,对照2组患者予丹参酮Ⅱ_(A)磺酸钠注射液静脉注射,观察组患者联用上述两药,3组均治疗1周。结果观察组总有效率为90.00%,显著高于对照1组的56.00%和对照2组的60.00%(P<0.05);治疗后,观察组患者的肿瘤坏死因子-α、超敏C反应蛋白、白细胞介素6、白细胞介素8、肠黏膜COX-2及NF-κB表达水平均显著低于对照1组和对照2组(P<0.05);3组间不良反应发生率相当(P>0.05)。结论美沙拉嗪联合丹参酮Ⅱ_(A)治疗溃疡性结肠炎有一定疗效,可下调患者肠黏膜COX-2和NF-κB表达水平,减轻肠黏膜炎性反应,较单用美沙拉嗪或丹参酮Ⅱ_(A)治疗更具优势。Objective To investigate the clinical efficacy of mesalazine combined with tanshinoneⅡ_(A)in the treatment of patients with ulcerative colitis and its effect on the expression levels of cyclooxygenase-2(COX-2)and nuclear factor-κB(NF-κB)in the intestinal mucosa of patients.Methods A total of 80 patients with ulcerative colitis admitted to our hospital from January 2018 to January 2020 were selected and divided into the control groupⅠ(25 cases),the control groupⅡ(25 cases)and the observation group(30 cases)according to the different treatment method.The patients in the control groupⅠwere treated with Mesalazine Enteric Coated Tablets,the patients in the control groupⅡwere treated with TanshinoneⅡ_(A)Sodium Sulfonate Injection by intravenous injection,while the patients in the observation group were treated with the above two drugs.The three groups were treated for one week.Results The total effective rate of the observation group was 90.00%,which was significantly higher than 56.00%of the control groupⅠand 60.00%of the control groupⅡ(P<0.05).After treatment,the levels of tumor necrosis factor-α(TNF-α),hypersensitive C-reactive protein(hs-CRP),interleukin-6(IL-6)and interleukin-8(IL-8),the expression levels of COX-2 and NF-κB in the intestinal mucosa in the observation group were significantly lower than those in control groupⅠand control groupⅡ(P<0.05).The incidence of adverse reactions was similar among the three groups(P>0.05).Conclusion Mesalazine combined with tanshinoneⅡ_(A)is effective in the treatment of patients with ulcerative colitis,it can down-regulate the expression levels of COX-2 and NF-κB in the intestinal mucosa,which is superior to mesalazine and tanshinoneⅡ_(A)alone.

关 键 词：溃疡性结肠炎 美沙拉嗪 丹参酮Ⅱ_(A) 炎性反应 临床疗效 

分 类 号：R969.4[医药卫生—药理学] R975.6[医药卫生—药学]